{"id":"https://openalex.org/W2092287139","doi":"https://doi.org/10.1016/j.clinthera.2012.04.013","title":"Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review","display_name":"Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review","publication_year":2012,"publication_date":"2012-05-18","ids":{"openalex":"https://openalex.org/W2092287139","doi":"https://doi.org/10.1016/j.clinthera.2012.04.013","mag":"2092287139","pmid":"https://pubmed.ncbi.nlm.nih.gov/22608780"},"language":"en","primary_location":{"id":"doi:10.1016/j.clinthera.2012.04.013","doi":"https://doi.org/10.1016/j.clinthera.2012.04.013","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.clinthera.2012.04.013","pdf_url":null,"source":{"id":"https://openalex.org/S185879095","display_name":"Clinical Therapeutics","issn_l":"0149-2918","issn":["0149-2918","1879-114X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Therapeutics","raw_type":"journal-article"},"volume":null,"type":"review","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://doi.org/10.1016/j.clinthera.2012.04.013","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5005405894","display_name":"Vanita R. Aroda","orcid":"https://orcid.org/0000-0002-7706-4585","observed_orcids":["https://orcid.org/0000-0002-7706-4585"]},"institutions":[{"id":"https://openalex.org/I4405281094","display_name":"MedStar Health Research Institute","ror":"https://ror.org/03vny0n12","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4405281094","https://openalex.org/I86755215"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Vanita R. Aroda","raw_affiliation_strings":["Department of Endocrinology, Diabetes, and Metabolism, MedStar Health Research Institute, Hyattsville, MD 20782, USA. Vanita.Aroda@Medstar.net","Department of Endocrinology, Diabetes, and Metabolism, MedStar Health Research Institute, Hyattsville, Maryland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Endocrinology, Diabetes, and Metabolism, MedStar Health Research Institute, Hyattsville, MD 20782, USA. Vanita.Aroda@Medstar.net","institution_ids":["https://openalex.org/I4405281094"]},{"raw_affiliation_string":"Department of Endocrinology, Diabetes, and Metabolism, MedStar Health Research Institute, Hyattsville, Maryland","institution_ids":["https://openalex.org/I4405281094"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045462483","display_name":"Robert R. Henry","orcid":"https://orcid.org/0000-0002-4821-0117","observed_orcids":["https://orcid.org/0000-0002-4821-0117"]},"institutions":[{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert R. Henry","raw_affiliation_strings":["Division of Endocrinology and Metabolism, University of California, San Diego, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Endocrinology and Metabolism, University of California, San Diego, California","institution_ids":["https://openalex.org/I36258959"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111694431","display_name":"Jenny Han","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jenny Han","raw_affiliation_strings":["Amylin Pharmaceuticals, Inc., San Diego, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amylin Pharmaceuticals, Inc., San Diego, California","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037345577","display_name":"Wenying Huang","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Wenying Huang","raw_affiliation_strings":["Amylin Pharmaceuticals, Inc., San Diego, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amylin Pharmaceuticals, Inc., San Diego, California","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010846329","display_name":"Mary Beth DeYoung","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mary Beth DeYoung","raw_affiliation_strings":["Amylin Pharmaceuticals, Inc., San Diego, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amylin Pharmaceuticals, Inc., San Diego, California","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069521580","display_name":"Tamara Darsow","orcid":"https://orcid.org/0000-0002-6650-6368","observed_orcids":["https://orcid.org/0000-0002-6650-6368"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tamara Darsow","raw_affiliation_strings":["Amylin Pharmaceuticals, Inc., San Diego, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amylin Pharmaceuticals, Inc., San Diego, California","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5058778822","display_name":"Byron J. Hoogwerf","orcid":"https://orcid.org/0000-0001-6014-4151","observed_orcids":["https://orcid.org/0000-0001-6014-4151"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Byron J. Hoogwerf","raw_affiliation_strings":["Eli Lilly and Company Indianapolis Indiana"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company Indianapolis Indiana","institution_ids":["https://openalex.org/I168537998"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":4240,"currency":"USD","value_usd":4240},"apc_paid":{"value":4240,"currency":"USD","value_usd":4240},"fwci":5.1414,"has_fulltext":false,"cited_by_count":253,"citation_normalized_percentile":{"value":0.9787408,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":97,"max":100},"biblio":{"volume":"34","issue":"6","first_page":"1247","last_page":"1258.e22"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12539","display_name":"Pharmacology and Obesity Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9100000262260437},{"id":"https://openalex.org/keywords/incretin-based-therapy","display_name":"incretin-based therapy","score":0.9049999713897705},{"id":"https://openalex.org/keywords/glp-1-receptor-agonists","display_name":"GLP-1 receptor agonists","score":0.9860000014305115},{"id":"https://openalex.org/keywords/dpp-4-inhibitors","display_name":"DPP-4 inhibitors","score":0.9990000128746033},{"id":"https://openalex.org/keywords/hba1c","display_name":"HbA1c","score":0.628000020980835},{"id":"https://openalex.org/keywords/fasting-blood-glucose","display_name":"fasting blood glucose","score":0.9279999732971191},{"id":"https://openalex.org/keywords/weight-loss","display_name":"weight loss","score":0.906000018119812},{"id":"https://openalex.org/keywords/exenatide","display_name":"exenatide","score":0.984000027179718},{"id":"https://openalex.org/keywords/liraglutide","display_name":"liraglutide","score":0.9980000257492065},{"id":"https://openalex.org/keywords/vildagliptin","display_name":"vildagliptin","score":0.9789999723434448},{"id":"https://openalex.org/keywords/exenatide-twice-daily","display_name":"exenatide twice daily","score":0.6610000133514404},{"id":"https://openalex.org/keywords/treatment-efficacy-comparison","display_name":"treatment efficacy comparison","score":0.5450000166893005}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9233384132385254},{"id":"https://openalex.org/C95190672","wikidata":"https://www.wikidata.org/wiki/Q815382","display_name":"Meta-analysis","level":2,"score":0.6676034331321716},{"id":"https://openalex.org/C2778881409","wikidata":"https://www.wikidata.org/wiki/Q1420402","display_name":"Incretin","level":4,"score":0.6537471413612366},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.583472728729248},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.561730682849884},{"id":"https://openalex.org/C2779473830","wikidata":"https://www.wikidata.org/wiki/Q1540899","display_name":"MEDLINE","level":2,"score":0.501856803894043},{"id":"https://openalex.org/C2776442814","wikidata":"https://www.wikidata.org/wiki/Q6659956","display_name":"Lixisenatide","level":5,"score":0.49175265431404114},{"id":"https://openalex.org/C2779284873","wikidata":"https://www.wikidata.org/wiki/Q419832","display_name":"Sitagliptin","level":4,"score":0.48904380202293396},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.451218843460083},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.448571115732193},{"id":"https://openalex.org/C156490143","wikidata":"https://www.wikidata.org/wiki/Q412214","display_name":"Dipeptidyl peptidase-4","level":4,"score":0.4385644495487213},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.43612736463546753},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.42154181003570557},{"id":"https://openalex.org/C2776398474","wikidata":"https://www.wikidata.org/wiki/Q424611","display_name":"Glucagon-like peptide-1","level":4,"score":0.41291964054107666},{"id":"https://openalex.org/C2780533449","wikidata":"https://www.wikidata.org/wiki/Q417762","display_name":"Exenatide","level":4,"score":0.3040156364440918},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.23017045855522156},{"id":"https://openalex.org/C199539241","wikidata":"https://www.wikidata.org/wiki/Q7748","display_name":"Law","level":1,"score":0.0},{"id":"https://openalex.org/C17744445","wikidata":"https://www.wikidata.org/wiki/Q36442","display_name":"Political science","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000067757","descriptor_name":"Glucagon-Like Peptide-1 Receptor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001835","descriptor_name":"Body Weight","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018027","descriptor_name":"Receptors, Glucagon","qualifier_ui":"Q000819","qualifier_name":"agonists","is_major_topic":true},{"descriptor_ui":"D054873","descriptor_name":"Dipeptidyl-Peptidase IV Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D054873","descriptor_name":"Dipeptidyl-Peptidase IV Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1016/j.clinthera.2012.04.013","doi":"https://doi.org/10.1016/j.clinthera.2012.04.013","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.clinthera.2012.04.013","pdf_url":null,"source":{"id":"https://openalex.org/S185879095","display_name":"Clinical Therapeutics","issn_l":"0149-2918","issn":["0149-2918","1879-114X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Therapeutics","raw_type":"journal-article"},{"id":"pmid:22608780","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/22608780","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical therapeutics","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1016/j.clinthera.2012.04.013","doi":"https://doi.org/10.1016/j.clinthera.2012.04.013","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.clinthera.2012.04.013","pdf_url":null,"source":{"id":"https://openalex.org/S185879095","display_name":"Clinical Therapeutics","issn_l":"0149-2918","issn":["0149-2918","1879-114X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Therapeutics","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/systematic-review","display_name":"Systematic Review"},{"id":"https://openalex.org/study-designs/meta-analysis","display_name":"Meta-Analysis"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"},{"id":"https://openalex.org/F4320307768","display_name":"Amylin Pharmaceuticals","ror":"https://ror.org/043cec594"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":94,"referenced_works":["https://openalex.org/W100598291","https://openalex.org/W1484868350","https://openalex.org/W1532170875","https://openalex.org/W1585447752","https://openalex.org/W1928513790","https://openalex.org/W1966469183","https://openalex.org/W1969389642","https://openalex.org/W1970125713","https://openalex.org/W1971471384","https://openalex.org/W1977119153","https://openalex.org/W1977619586","https://openalex.org/W1981183973","https://openalex.org/W1984740259","https://openalex.org/W1986085856","https://openalex.org/W1991951001","https://openalex.org/W1994832750","https://openalex.org/W1995628618","https://openalex.org/W1998717083","https://openalex.org/W1999892372","https://openalex.org/W2005379446","https://openalex.org/W2008132861","https://openalex.org/W2012117258","https://openalex.org/W2018192866","https://openalex.org/W2020292843","https://openalex.org/W2025995365","https://openalex.org/W2027249582","https://openalex.org/W2028092672","https://openalex.org/W2028272916","https://openalex.org/W2031468509","https://openalex.org/W2041342486","https://openalex.org/W2043900831","https://openalex.org/W2045753702","https://openalex.org/W2048728983","https://openalex.org/W2050826565","https://openalex.org/W2051462052","https://openalex.org/W2058468402","https://openalex.org/W2061865937","https://openalex.org/W2066046508","https://openalex.org/W2071835038","https://openalex.org/W2072691447","https://openalex.org/W2074142099","https://openalex.org/W2077969859","https://openalex.org/W2078561985","https://openalex.org/W2079160676","https://openalex.org/W2079787842","https://openalex.org/W2083808413","https://openalex.org/W2085862152","https://openalex.org/W2086842286","https://openalex.org/W2087025850","https://openalex.org/W2098459806","https://openalex.org/W2098905490","https://openalex.org/W2101246901","https://openalex.org/W2102511839","https://openalex.org/W2103058881","https://openalex.org/W2103364479","https://openalex.org/W2106154942","https://openalex.org/W2107949845","https://openalex.org/W2113367996","https://openalex.org/W2113901579","https://openalex.org/W2114702224","https://openalex.org/W2114927834","https://openalex.org/W2124943649","https://openalex.org/W2125880609","https://openalex.org/W2126528659","https://openalex.org/W2128648250","https://openalex.org/W2129377335","https://openalex.org/W2129578585","https://openalex.org/W2133244310","https://openalex.org/W2137352234","https://openalex.org/W2137471483","https://openalex.org/W2138077952","https://openalex.org/W2138290933","https://openalex.org/W2138897693","https://openalex.org/W2139230122","https://openalex.org/W2139485303","https://openalex.org/W2140480989","https://openalex.org/W2141132900","https://openalex.org/W2141946042","https://openalex.org/W2145335273","https://openalex.org/W2148798434","https://openalex.org/W2152969995","https://openalex.org/W2152984355","https://openalex.org/W2158727328","https://openalex.org/W2159198773","https://openalex.org/W2159205789","https://openalex.org/W2160001758","https://openalex.org/W2162934281","https://openalex.org/W2164416879","https://openalex.org/W2166173635","https://openalex.org/W2170606300","https://openalex.org/W2171512247","https://openalex.org/W2325963726","https://openalex.org/W2509949587","https://openalex.org/W6676864473"],"related_works":["https://openalex.org/W2514777534","https://openalex.org/W2058514432","https://openalex.org/W1919558603","https://openalex.org/W2791740462","https://openalex.org/W2079505490","https://openalex.org/W2091480327","https://openalex.org/W1579987784","https://openalex.org/W2067736115","https://openalex.org/W2011184145","https://openalex.org/W2106031348"],"abstract_inverted_index":{"BACKGROUND:":[0],"Considerable":[1],"clinical":[2,172],"data":[3],"on":[4],"the":[5,34,37,42,47,78,87,94,99,138,182,208,211,256,260,268,271,285,317,321,340,343,348],"treatment":[6,95,312],"of":[7,36,46,80,96,101,122,174,207,223,262,284,291,306,316],"type":[8],"2":[9],"diabetes":[10],"with":[11,216,236,250,259,267,300,326],"incretin-based":[12,48,318],"therapies":[13,319],"(glucagon-like":[14],"peptide":[15],"1":[16],"receptor":[17],"agonists":[18],"[GLP-1RAs]":[19],"and":[20,55,69,90,98,128,153,196,210,227,255,270,276,296,333,342,346],"dipeptidyl-peptidase":[21],"IV":[22],"[DPP-4]":[23],"inhibitors)":[24],"are":[25,109,351],"available.":[26],"OBJECTIVE:":[27],"This":[28],"meta-analysis":[29,323],"was":[30],"performed":[31],"to":[32,124,192,198,225,229,278],"support":[33],"understanding":[35],"overall":[38],"evidence":[39],"by":[40,86],"summarizing":[41],"findings":[43],"from":[44,131,190,218,329],"studies":[45,338],"therapies.":[49,165],"METHODS:":[50],"The":[51,142,167,203,282],"MEDLINE,":[52],"EMBASE,":[53],"BIOSIS,":[54],"BIOSIS":[56],"trial":[57],"databases":[58],"were":[59,114,118,177,214,245,274,324],"searched":[60],"for":[61,93,156,179,293,311],"relevant":[62],"literature":[63],"published":[64],"between":[65,164,339],"January":[66],"1,":[67],"1990,":[68],"June":[70],"30,":[71],"2011.":[72],"Search":[73],"terms":[74],"included":[75,115,288],"GLP-1,":[76],"DPP-4,":[77],"names":[79,100],"drugs":[81,102],"that":[82,103],"have":[83,104],"been":[84,106],"approved":[85,107],"US":[88],"Food":[89],"Drug":[91],"Administration":[92],"diabetes,":[97],"not":[105,161],"but":[108,159],"in":[110,133,181,220,234,302,320,331],"late-stage":[111],"research.":[112],"Studies":[113],"if":[116],"they":[117],"randomized":[119],"controlled":[120],"trials":[121],"12":[123],"52":[125],"weeks'":[126],"duration":[127],"having":[129],"change":[130],"baseline":[132,186,219,330],"hemoglobin":[134],"(Hb)":[135],"A(1c)":[136],"as":[137],"primary":[139],"end":[140],"point.":[141],"random":[143],"effects":[144,163],"meta-analyses":[145],"models":[146],"examined":[147],"HbA(1c),":[148],"fasting":[149],"plasma":[150],"glucose":[151],"(FPG),":[152],"body":[154],"weight":[155,265],"individual":[157],"therapies,":[158],"did":[160],"compare":[162],"RESULTS:":[166],"reviewers":[168],"identified":[169],"362":[170],"unique":[171],"studies,":[173],"which":[175],"80":[176],"eligible":[178],"inclusion":[180],"present":[183,286,322],"meta-analysis.":[184],"Mean":[185,232,264],"HbA(1c)":[187,222,332],"values":[188],"ranged":[189],"7.4%":[191],"10.3%":[193],"(GLP-1RA":[194],"studies)":[195],"7.2%":[197],"9.3%":[199],"(DPP-4":[200],"inhibitor":[201],"studies).":[202],"highest":[204],"maintenance":[205],"doses":[206],"GLP-1RAs":[209,269,341],"DPP-4":[212,257,272,344],"inhibitors":[213,273,345],"associated":[215,299,325],"changes":[217],"mean":[221],"-1.1%":[224],"-1.6%":[226],"-0.6%":[228],"-1.1%,":[230],"respectively.":[231,281],"reductions":[233,328],"FPG":[235],"exenatide":[237,251],"once":[238,243],"weekly":[239],"(QW)":[240],"or":[241],"liraglutide":[242],"daily":[244,253],"apparently":[246],"greater":[247],"than":[248],"those":[249],"twice":[252],"(BID)":[254],"inhibitors,":[258],"exception":[261],"vildagliptin.":[263],"losses":[266],">-2.0":[275],"-0.2":[277],"-0.6":[279],"kg,":[280],"limitations":[283],"analysis":[287],"a":[289],"lack":[290],"adjustment":[292],"placebo":[294],"use":[295],"interstudy":[297],"heterogeneity":[298],"differences":[301],"methodology":[303],"(eg,":[304],"management":[305],"concurrent":[307],"medications,":[308],"blinding,":[309],"criteria":[310],"discontinuation).":[313],"CONCLUSIONS:":[314],"All":[315],"significant":[327],"FPG.":[334],"Further":[335],"direct":[336],"comparative":[337],"within":[347],"GLP-1RA":[349],"class":[350],"justified.":[352]},"counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":11},{"year":2024,"cited_by_count":8},{"year":2023,"cited_by_count":5},{"year":2022,"cited_by_count":6},{"year":2021,"cited_by_count":12},{"year":2020,"cited_by_count":10},{"year":2019,"cited_by_count":13},{"year":2018,"cited_by_count":26},{"year":2017,"cited_by_count":18},{"year":2016,"cited_by_count":24},{"year":2015,"cited_by_count":34},{"year":2014,"cited_by_count":35},{"year":2013,"cited_by_count":38},{"year":2012,"cited_by_count":9}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}